Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 823

TitleReference numberPublishedLast updated
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055
Molnupiravir for treating COVID-19TA1056
Relugolix–estradiol–norethisterone for treating symptoms of endometriosisTA1057
Cladribine for treating active relapsing forms of multiple sclerosisTA1053
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTA1054
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and overTA1051
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)TA1052
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitableTA1048
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTA1049
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTA1050

Results per page

  1. 10
  2. 25
  3. 50
  4. All